In An Updated Analysis From Phase 3 NATALEE Trial Of Novartis' Kisqali (Ribociclib) Added To Endocrine Therapy Shows Deepening Benefit Beyond Three-year Treatment Period, Reducing Risk Of Recurrence By 28.5%, Compared To ET Alone, For Stage II And III...
In An Updated Analysis From Phase 3 NATALEE Trial Of Novartis' Kisqali (Ribociclib) Added To Endocrine Therapy Shows Deepening Benefit Beyond Three-year Treatment Period, Reducing Risk Of Recurrence By 28.5%, Compared To ET Alone, For Stage II And III...
根據諾華(Kisqali)的NATALEE III期試驗的最新分析結果顯示，在激素治療期間添加該藥物能夠在三年治療期後持續減少28.5%的復發風險，相較於單獨使用激素治療，對於II期和III期激素受體陽性/人類表皮生長因子受體2陰性的早期乳腺癌有進一步的益處。
In An Updated Analysis From Phase 3 NATALEE Trial Of Novartis' Kisqali (Ribociclib) Added To Endocrine Therapy Shows Deepening Benefit Beyond Three-year Treatment Period, Reducing Risk Of Recurrence By 28.5%, Compared To ET Alone, For Stage II And III Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer
根據諾華(Kisqali)的NATALEE III期試驗的最新分析結果顯示，在激素治療期間添加該藥物能夠在三年治療期後持續減少28.5%的復發風險，相較於單獨使用激素治療，對於II期和III期激素受體陽性/人類表皮生長因子受體2陰性的早期乳腺癌有進一步的益處。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。